EU rejects obesity drug Qsiva for the second time
Despite an appeal by Vivus, the European Medicines Agency has rejected the obesity treatment phentermine/topiramate ER for the second time. Any benefit "does not outweigh the risks," says the EMA.
Source: theHeart.org - Category: Cardiology Source Type: news
More News: Adipex | Cardiology | Eating Disorders & Weight Management | European Medicines Agency (EMA) | Obesity | Phentermine | Topamax